'Specific mortality' diaporamas de présentation

??????? ?????? ? ?????? ?? ???????

??????? ?????? ? ?????? ?? ???????. ?.?. ?????????. Causes of death and their classification. Established by the World Health Organization as International Classification of Diseases (ICD)

1.16k views • 89 slides

Strategic Planning & Community Strategy Mapping for Public Health Systems & Agencies

Strategic Planning & Community Strategy Mapping for Public Health Systems & Agencies. Jack Moran, Public Health Foundation. Paul Epstein, Results That Matter Team. Introduction . Public Health Foundation www.phf.org

1.02k views • 62 slides

Strategic Planning & Community Strategy Mapping for Public Health Systems & Agencies

Strategic Planning & Community Strategy Mapping for Public Health Systems & Agencies. Jack Moran, Public Health Foundation. Paul Epstein, Results That Matter Team. Introduction . Public Health Foundation www.phf.org

723 views • 62 slides

Modelling Needs and Resources of Older People to 2030 (NaROP2030)

653 views • 56 slides

The Pratt & Whitney Epidemiology Study Phase 1 (Cohort Mortality)

The Pratt & Whitney Epidemiology Study Phase 1 (Cohort Mortality). Presentation of Phase 1 Results September 18, 2008. Purpose of the Study. To investigate the earlier perception of an unusual occurrence of glioblastoma at the P&W North Haven facility. P&W Study Highlights.

485 views • 34 slides

STANDARDIZED RATES AND RATIOS

STANDARDIZED RATES AND RATIOS. Nigel Paneth. MORTALITY RATES. (mortality rates are usually incidence rates, and therefore need a time dimension). 1. (All-cause or crude) mortality rate = total deaths in a year Estimate of people alive during that year*

517 views • 34 slides

STANDARDIZED RATES AND RATIOS

STANDARDIZED RATES AND RATIOS. Nigel Paneth. MORTALITY RATES. (mortality rates are usually incidence rates, and therefore need a time dimension). 1. (All-cause or crude) mortality rate = total deaths in a year Estimate of people alive during that year*

425 views • 34 slides

Thoughts on Biomarker Discovery and Validation

Thoughts on Biomarker Discovery and Validation. Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007. Outline. General guidelines Objectives of screening studies Phase I: Pre-clinical exploratory studies Phase II: Clinical assay development for clinical disease

683 views • 30 slides

273 views • 27 slides

FDG-PET Detected Thyroid Incidentaloma

FDG-PET Detected Thyroid Incidentaloma. Dr. LP Si Yan Chai Hospital. Background. With the increasing use of imaging modalities, more and more clinically inconspicuous thyroid lesions are discovered These are termed as thyroid incidentalomas

632 views • 26 slides

Technical Overview

ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski , MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012. Technical Overview. 1. PMTCT Options and ART Regimens Recognized in WHO PMTCT Programmatic Update 2012 2 . Who needs ART? 3 . Benefits of ART

378 views • 22 slides

Statistical analysis of Mortality in Lithuania,Belarus,Russia

241 views • 14 slides

HEALTH HAZARDS of GLOBAL COOLING

HEALTH HAZARDS of GLOBAL COOLING. Howard Maccabee, PhD, MD The 2009 Intl. Conf. on Climate Change New York City. The IPCC projections are wrong. 1976. 1981. Ice Ice Age. Makes Man?. 2007. Quiet sun ? More Cosmic Rays ? More Clouds ? Colder Climate.

154 views • 14 slides

USRDS: Cause-specific mortality in ESRD patients undergoing revascularization

USRDS: Cause-specific mortality in ESRD patients undergoing revascularization. Herzog C. American Heart Association Scientific Sessions 2004; Nov 7-10, 2004; New Orleans, LA. USRDS/NRMI: Clinical characteristics and outcome in dialysis, nondialysis and nonrenal patients.

134 views • 2 slides